Phase 2 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Reltecimod (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Atox Bio
- 05 Feb 2018 Planned initiation date changed from 1 Apr 2019 to 1 Apr 2018.
- 05 Dec 2017 New trial record
- 04 Dec 2017 According to an Atox Bio media release, the company plans to initiate this trial during 2018.